{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T05:51:12Z","timestamp":1711518672140},"reference-count":11,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.clinthera.2017.08.009","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T05:45:54Z","timestamp":1505799954000},"page":"2024-2037","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds"],"prefix":"10.1016","volume":"39","author":[{"given":"Ira","family":"Gantz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liubov","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lokesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Iredale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailaja","family":"Suryawanshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.08.009_bib1","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1021\/jm401992e","article-title":"Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes","volume":"57","author":"Biftu","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2017.08.009_bib2","first-page":"S55","article-title":"Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial","volume":"57","author":"Gantz","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2017.08.009_bib3","first-page":"S54","article-title":"Omarigliptin, a once-weekly DPP-4 inhibitor, provides similar glycemic control to sitagliptin in patients with T2DM inadequately controlled on metformin","volume":"58","author":"Gantz","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2017.08.009_bib4","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang","year":"2000","journal-title":"Indian J Statistics"},{"key":"10.1016\/j.clinthera.2017.08.009_bib5","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/dc15-0109","article-title":"Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes","volume":"38","author":"Sheu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.08.009_bib6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/dom.12832","volume":"19","author":"Goldenberg","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2017.08.009_bib7","first-page":"A50","article-title":"Omarigliptin, a once-weekly DPP-4 inhibitor, improves glycemic control in patients inadequately controlled on the combination of metformin and glimepiride","volume":"65","author":"Lee","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2017.08.009_bib8","first-page":"A318","article-title":"Omarigliptin improves glycemic control and is well tolerated as add-on therapy to oral antihyperglycemic agents in Japanese patients with type 2 diabetes","volume":"64","author":"Gantz","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2017.08.009_bib9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jlme.12093","article-title":"Subversive subjects: rule-breaking and deception in clinical trials","volume":"41","author":"Dresser","year":"2013","journal-title":"J Law Med Ethics"},{"key":"10.1016\/j.clinthera.2017.08.009_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/ajp.147.4.507","article-title":"Surreptitious drug use by patients in a panic disorder study","volume":"147","author":"Clark","year":"1990","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2017.08.009_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/1740774513492917","article-title":"Concealment and fabrication by experienced research subjects","volume":"10","author":"Devine","year":"2013","journal-title":"Clin Trials"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817308986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817308986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T11:23:58Z","timestamp":1535369038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817308986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0149291817308986"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.08.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}